TLDR
- Kalshi added new markets letting users bet on clinical trial outcomes and FDA approval decisions.
- The company says market pricing could reveal information that often stays hidden during drug development.
- The first contracts include a therapy from Gilead and Arcellx for multiple myeloma.
- A separate market covers AR1001, an Alzheimer’s drug currently in Phase III testing.
- FDA data shows almost three in ten required trials failed to report results on time.
Kalshi is adding a new category of markets focused on drug research. The platform will let users place trades on whether experimental medicines pass clinical trials and win approval from the Food and Drug Administration.
This is a shift for the company. Kalshi has mostly built its business around sports, weather, and political outcomes.
The company frames this move as more than gambling. It says public prediction markets can surface information that usually stays hidden while drugs move through development.
Why Kalshi Is Entering Drug Research
Drug trial reporting has faced criticism for years. Companies are required to post results on ClinicalTrials.gov, but many do not follow through.
An FDA review found that close to three in ten studies subject to mandatory disclosure rules never submitted their results. That leaves gaps in public knowledge about how treatments are performing.
Kalshi argues that trading prices could fill some of that gap. Instead of waiting on company press releases, users could watch probabilities shift in real time based on trading activity.
The idea is that investors, doctors, researchers, and patients would all have access to the same live data. Kalshi says the rollout will happen gradually and follow existing regulatory rules.
First Markets Set to Launch
One of the first contracts tracks the FDA’s expected December decision on anito-cel. The therapy is a CAR-T treatment for relapsed or refractory multiple myeloma being developed by Gilead and Arcellx.
Traders will be able to bet on whether the FDA approves the treatment. The decision is expected before the end of the year.
A second market focuses on AR1001, an experimental Alzheimer’s treatment. This contract will track whether the drug’s ongoing Phase III trial meets its primary goal.
That trial outcome could shape the drug’s future development path. It is one of the more closely watched studies in the Alzheimer’s treatment space.
Kalshi has not said how many additional drug-related markets it plans to add. The company indicated more contracts will follow as the category grows.
The expansion puts prediction markets into an area usually handled by scientific researchers and health regulators. Clinical trial results and FDA rulings can move stock prices, making this data attractive to traders.
Gilead and Arcellx shares often react to news about anito-cel’s trial progress. A Kalshi market tied to the drug’s approval odds would give traders another way to track sentiment outside of the stock market itself.
The December FDA decision date remains the closest milestone tied to Kalshi’s new markets. Traders and industry watchers are expected to focus on that date first as the new contracts go live.
